Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

This study evaluates the safety, effectiveness, and how the body processes a new investigational drug called EVER001 for the treatment of primary membranous nephropathy (MN). Primary membranous nephropathy is a kidney disease in which the body's immune system mistakenly attacks proteins on the kidney's own filtering cells, causing protein to leak into the urine (a condition called nephrotic syndrome). This leads to severe swelling, vulnerability to blood clots and infections, and eventually kidney failure if untreated. The main target in most cases is a protein called PLA2R, and the immune attack is driven by a specific type of immune cell called B cells. Eligible participants are adults aged 18 to 75 with a biopsy-proven diagnosis of primary membranous nephropathy who have high levels of the PLA2R antibody in their blood, protein leakage in their urine above a certain threshold despite supportive treatment with blood pressure medications, and adequate kidney function (eGFR above 45). Participants receive EVER001 by injection and are followed to measure changes in urinary protein, antibody levels, kidney function, and safety markers over time. This research is significant because existing treatments for MN — including immunosuppressive chemotherapy and rituximab — carry substantial risks and are not effective for all patients. A targeted therapy like EVER001 that specifically blocks the B cell response driving the disease could offer a safer and more effective option for patients living with this difficult kidney condition.